Full notification file
Member State to which the notification was sent
Date of acknowledgement from the Member State Competent Authority
Title of the Project
Gene therapy Clinical development program comprising of clinical trials using SAR422459, a non-replicating, recombinant lentiviral vector derived from Equine Infectious Anemia Virus (EIAV) to express ATP Binding Cassette A4 (ABCA4) transporter and correct its defective expression or function in photoreceptors of patients with Stargardt macular dystrophy and other ABCA4 retinopathies.
Proposed period of release:
01/01/2015 to 01/11/2050
Name of the Institute(s) or Company(ies)
Aanofi-Aventis Groupe, ;
3. Is the same GMO release planned elsewhere in the Community?
Has the same GMO been notified elsewhere by the same notifier?
GMO is a:
Identity of the GMO:
Species: Equine Infectious Anemia Virus (EIAV)
SAR422459, replication -defective vector based on a lentivirus, Equine Infectious Anemia Virus (EIAV), pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-G: rhabdovirus) envelop
Information relating to the recipient or parental organisms from wich the GMO is derived
Equine Infectious Anemia Virus
European Commission administrative information
Consent given by the Member State Competent Authority: